Skip to content

Total debt at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$691.72M+334%
Arrowhead Research logo
Arrowhead ResearchARWR
$107.88M-5.6%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$3.79M-16.8%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$395.09M+0.1%
Scholar Rock logo
Scholar RockSRRK
$205.67M+226%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$2.68M-13.3%

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.27B+153%
Enterprise value$2.69B+228%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Calculated from Dyne Therapeutics, Inc.’s reported figures.

Plus components not separately reported this period.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s total debt?
Dyne Therapeutics, Inc. (DYN) reported total debt of $168.68M in Q1 2026.
How has Dyne Therapeutics, Inc.'s total debt changed year-over-year?
Dyne Therapeutics, Inc.'s total debt increased by 623.0% year-over-year, from $23.33M to $168.68M.
What is the long-term trend for Dyne Therapeutics, Inc.'s total debt?
Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s total debt has grown at a 191.8% compound annual growth rate (CAGR), from $800K to $169.2M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.